Table 3.
25(OH) vitamin D levels and vitamin D deficiency prevalence among the different disease outcomes and characteristics in whole cohort of COVID-19 patients
| 25(OH) vitamin D levels (ng/mL) | P value | ||
|---|---|---|---|
| Hospitalization, yes/no | Yes (n.62): 13.5 [8–20] | No (n.11): 13.2 [10–22] | 0.78 |
| NIMV, yes/no | Yes (n.18): 8.5 [6–16] | No (n.55): 14.4 [11–23] | 0.003 |
| ICU, yes/no | Yes (n.8): 6.9 [6–10.4] | No (n.65): 14 [9.7–21] | 0.01 |
| Death, yes/no | Yes (n.3): 13 [8–22] | No (n.70): 13.2 [9–20] | 0.55 |
| Critical disease, yes/no | Yes (n.46): 11.7 [7–17] | No (n.27): 16.7 [11–31] | 0.007 |
| ALI-ARDS, yes/no | Yes (n.43): 10.8 [7–11] | No (n.30): 17 [13–29] | <0.001 |
| Hyperinflammation, yes/no | Yes (n.32): 11.2 [7.8–17] | No (41): 16.2 [10.7–23.2] | 0.039 |
| Vitamin D deficiency, n. (%) | |||
|---|---|---|---|
| Hospitalization, yes/no | Yes: 47 (75.8%) | No: 8 (72.7%) | >0.99 |
| NIMV, yes/no | Yes: 17 (94%) | No: 38 (69%) | 0.032 |
| ICU, yes/no | Yes: 7 (87%) | No: 48 (74%) | 0.67 |
| Death, yes/no | Yes: 1 (33.3%) | No: 54 (77%) | 0.15 |
| Critical disease, yes/no | Yes: 39 (85%) | No: 16 (59%) | 0.015 |
| ALI-ARDS, yes/no | Yes: 39 (91%) | No: 16 (53%) | 0.001 |
| Hyperinflammation, yes/no | Yes: 28 (87%) | No: 27 (66%) | 0.054 |
n. number, NIMV non-invasive mechanical ventilation, ICU intensive care unit, ALI Acute Lung Injury, ARDS Acute Respiratory-Distress Syndrome
P values reported in bold are those statistically significant